105 related articles for article (PubMed ID: 20875489)
1. Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage.
Ala'aldeen DA; Flint M; Oldfield NJ; Omer SA; McNeil LK; Jiang Q; Murphy E; Giardina PC; Novikova EG; Dodge-Scully IL; Bayliss CD; Turner DP; Neal KR; Hoiseth SK; Jansen KU; Anderson AS
Vaccine; 2010 Nov; 28(48):7667-75. PubMed ID: 20875489
[TBL] [Abstract][Full Text] [Related]
2. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease.
Jiang HQ; Hoiseth SK; Harris SL; McNeil LK; Zhu D; Tan C; Scott AA; Alexander K; Mason K; Miller L; DaSilva I; Mack M; Zhao XJ; Pride MW; Andrew L; Murphy E; Hagen M; French R; Arora A; Jones TR; Jansen KU; Zlotnick GW; Anderson AS
Vaccine; 2010 Aug; 28(37):6086-93. PubMed ID: 20619376
[TBL] [Abstract][Full Text] [Related]
3. A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial.
Richmond PC; Nissen MD; Marshall HS; Lambert SB; Roberton D; Gruber WC; Jones TR; Arora A
Vaccine; 2012 Sep; 30(43):6163-74. PubMed ID: 22871351
[TBL] [Abstract][Full Text] [Related]
4. Gene variability and degree of expression of vaccine candidate factor H binding protein in clinical isolates of Neisseria meningitidis.
Kelly A; Jacobsson S; Hussain S; Olcén P; Mölling P
APMIS; 2013 Jan; 121(1):56-63. PubMed ID: 23030708
[TBL] [Abstract][Full Text] [Related]
5. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide.
McNeil LK; Murphy E; Zhao XJ; Guttmann S; Harris SL; Scott AA; Tan C; Mack M; DaSilva I; Alexander K; Mason K; Jiang HQ; Zhu D; Mininni TL; Zlotnick GW; Hoiseth SK; Jones TR; Pride MW; Jansen KU; Anderson AS
Vaccine; 2009 May; 27(25-26):3417-21. PubMed ID: 19200847
[TBL] [Abstract][Full Text] [Related]
6. Potential impact of the bivalent rLP2806 vaccine on Neisseria meningitidis carriage and invasive serogroup B disease.
Anderson AS; Hao L; Jiang Q; Harris SL; Jones TR; Perez JL; York L; Eiden J; Jansen KU
Hum Vaccin Immunother; 2013 Mar; 9(3):471-9. PubMed ID: 23249817
[TBL] [Abstract][Full Text] [Related]
7. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis.
Murphy E; Andrew L; Lee KL; Dilts DA; Nunez L; Fink PS; Ambrose K; Borrow R; Findlow J; Taha MK; Deghmane AE; Kriz P; Musilek M; Kalmusova J; Caugant DA; Alvestad T; Mayer LW; Sacchi CT; Wang X; Martin D; von Gottberg A; du Plessis M; Klugman KP; Anderson AS; Jansen KU; Zlotnick GW; Hoiseth SK
J Infect Dis; 2009 Aug; 200(3):379-89. PubMed ID: 19534597
[TBL] [Abstract][Full Text] [Related]
8. Intranasal immunization of mice with recombinant lipidated P2086 protein reduces nasal colonization of group B Neisseria meningitidis.
Zhu D; Barniak V; Zhang Y; Green B; Zlotnick G
Vaccine; 2006 Jun; 24(26):5420-5. PubMed ID: 16621173
[TBL] [Abstract][Full Text] [Related]
9. Binding of Complement Factor H (FH) Decreases Protective Anti-FH Binding Protein Antibody Responses of Infant Rhesus Macaques Immunized With a Meningococcal Serogroup B Vaccine.
Granoff DM; Costa I; Konar M; Giuntini S; Van Rompay KK; Beernink PT
J Infect Dis; 2015 Sep; 212(5):784-92. PubMed ID: 25676468
[TBL] [Abstract][Full Text] [Related]
10. A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups.
Hoiseth SK; Murphy E; Andrew L; Vogel U; Frosch M; Hellenbrand W; Abad R; Vazquez JA; Borrow R; Findlow J; Taha MK; Deghmane AE; Caugant DA; Kriz P; Musilek M; Mayer LW; Wang X; Macneil JR; York L; Tan CY; Jansen KU; Anderson AS
Pediatr Infect Dis J; 2013 Oct; 32(10):1096-101. PubMed ID: 23694830
[TBL] [Abstract][Full Text] [Related]
11. A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on generalized modules for membrane antigens (GMMA).
Koeberling O; Ispasanie E; Hauser J; Rossi O; Pluschke G; Caugant DA; Saul A; MacLennan CA
Vaccine; 2014 May; 32(23):2688-95. PubMed ID: 24704334
[TBL] [Abstract][Full Text] [Related]
12. Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease.
Litt DJ; Savino S; Beddek A; Comanducci M; Sandiford C; Stevens J; Levin M; Ison C; Pizza M; Rappuoli R; Kroll JS
J Infect Dis; 2004 Oct; 190(8):1488-97. PubMed ID: 15378443
[TBL] [Abstract][Full Text] [Related]
13. Contribution of factor H-Binding protein sequence to the cross-reactivity of meningococcal native outer membrane vesicle vaccines with over-expressed fHbp variant group 1.
Marini A; Rossi O; Aruta MG; Micoli F; Rondini S; Guadagnuolo S; Delany I; Henderson IR; Cunningham AF; Saul A; MacLennan CA; Koeberling O
PLoS One; 2017; 12(7):e0181508. PubMed ID: 28742866
[TBL] [Abstract][Full Text] [Related]
14. Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen.
Seib KL; Scarselli M; Comanducci M; Toneatto D; Masignani V
Expert Rev Vaccines; 2015 Jun; 14(6):841-59. PubMed ID: 25704037
[TBL] [Abstract][Full Text] [Related]
15. Seroprevalence of antibodies against fHbp and NadA, two potential vaccine antigens for Neisseria meningitidis.
Jacobsson S; Mölling P; Olcén P
Vaccine; 2009 Sep; 27(42):5755-9. PubMed ID: 19654065
[TBL] [Abstract][Full Text] [Related]
16. Development of immunity to serogroup B meningococci during carriage of Neisseria meningitidis in a cohort of university students.
Jordens JZ; Williams JN; Jones GR; Christodoulides M; Heckels JE
Infect Immun; 2004 Nov; 72(11):6503-10. PubMed ID: 15501781
[TBL] [Abstract][Full Text] [Related]
17. T-cell-stimulating protein A elicits immune responses during meningococcal carriage and human disease.
Robinson K; Wooldridge KG; Wells DB; Hasan A; Todd I; Robins A; James R; Ala'Aldeen DA
Infect Immun; 2005 Aug; 73(8):4684-93. PubMed ID: 16040981
[TBL] [Abstract][Full Text] [Related]
18. [Antibody response in subjects with meningococal disease and in healthy carriers of Neisseria meningitidis].
Natoli D; Tringali G; Puma G; Castellini S; Chiarini A
G Batteriol Virol Immunol; 1976; 69(1-6):64-70. PubMed ID: 828887
[TBL] [Abstract][Full Text] [Related]
19. Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines.
Konar M; Granoff DM; Beernink PT
J Infect Dis; 2013 Aug; 208(4):627-36. PubMed ID: 23715659
[TBL] [Abstract][Full Text] [Related]
20. A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults.
Sheldon EA; Schwartz H; Jiang Q; Giardina PC; Perez JL
Hum Vaccin Immunother; 2012 Jul; 8(7):888-95. PubMed ID: 22832260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
